- Home
- HBCP vs RIGL Comparison
HBCP vs RIGL Comparison
Compare HBCP & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBCP
- RIGL
- Stock Information
- Founded
- HBCP 1908
- RIGL 1996
- Country
- HBCP United States
- RIGL United States
- Employees
- HBCP N/A
- RIGL N/A
- Industry
- HBCP Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- HBCP Finance
- RIGL Health Care
- Exchange
- HBCP Nasdaq
- RIGL Nasdaq
- Market Cap
- HBCP 342.0M
- RIGL 335.5M
- IPO Year
- HBCP 2008
- RIGL 2000
- Fundamental
- Price
- HBCP $50.78
- RIGL $18.88
- Analyst Decision
- HBCP Buy
- RIGL Buy
- Analyst Count
- HBCP 2
- RIGL 5
- Target Price
- HBCP $57.50
- RIGL $36.40
- AVG Volume (30 Days)
- HBCP 61.0K
- RIGL 170.2K
- Earning Date
- HBCP 07-16-2025
- RIGL 08-05-2025
- Dividend Yield
- HBCP 2.12%
- RIGL N/A
- EPS Growth
- HBCP 0.90
- RIGL N/A
- EPS
- HBCP 4.78
- RIGL 2.08
- Revenue
- HBCP $135,421,000.00
- RIGL $203,077,000.00
- Revenue This Year
- HBCP $0.25
- RIGL $14.41
- Revenue Next Year
- HBCP $5.18
- RIGL $15.97
- P/E Ratio
- HBCP $10.66
- RIGL $8.92
- Revenue Growth
- HBCP 3.44
- RIGL 70.16
- 52 Week Low
- HBCP $37.35
- RIGL $7.48
- 52 Week High
- HBCP $52.77
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- HBCP 58.65
- RIGL 37.91
- Support Level
- HBCP $48.30
- RIGL $18.35
- Resistance Level
- HBCP $51.95
- RIGL $19.21
- Average True Range (ATR)
- HBCP 1.08
- RIGL 0.89
- MACD
- HBCP 0.03
- RIGL -0.33
- Stochastic Oscillator
- HBCP 77.53
- RIGL 2.15
About HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.